The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2023 | The addition of venetoclax to HMAs for the treatment of CMML: a retrospective PSM analysis
Douglas Tremblay, MD, Icahn School of Medicine at Mount Sinai, New York, NY, discusses the findings of a retrospective analysis of data from four academic centers, which aimed to compare the response rates and survival outcomes of patients with chronic myelomonocytic leukemia (CMML) treated with hypomethylating agents (HMA) with or without venetoclax. Using a propensity score-matched (PSM) analysis, the addition of venetoclax to treatment regimens was found to improve response rates of patients but conferred no benefit to survival outcomes. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
